ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 609

Peripheral Neuropathy in Systemic Lupus Erythematosus

Amin Oomatia1, Hong Fang2, Michelle Petri2 and Julius Birnbaum3, 1School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatology, Johns Hopkins University, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: neurologic involvement and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Whilst Neurological disorders are a common manifestation of systemic lupus erythematosus (SLE), peripheral neuropathies have received little attention. The literature consists mostly of small case series with very few studies investigating larger samples. Consequently, various features of SLE-associated peripheral neuropathies such as prevalence, symptoms, severity, chronicity, clinical and serological associations, and electrophysiological and biopsy findings, are poorly described. Small fibre neuropathies are almost entirely un-reported. The aim of this study is to determine the prevalence, clinical features, electrophysiological and biopsy findings of peripheral neuropathies in systemic lupus erythematosus and to identify clinical and laboratory correlations.

Methods: We performed a retrospective study of 2,097 SLE patients seen at a single Center since 1987, and ascertained for the presence of neuropathy according to diagnostic criteria laid down by the American Academy of Neurology.   We categorized subtypes of peripheral neuropathies on the basis of symptoms, examination, electrophysiological studies, and punch skin biopsy features. We excluded patients with co-morbid features associated with neuropathies.   We evaluated for an association of demographic, SLE-related clinical features, antibodies, and other immunological data in SLE patients with neuropathies versus without neuropathies by student’s t-test or chi-squared test, with p-values <0.05 considered statistically significant.

Results: The prevalence of neuropathies was 4.4%, present in 82 of 2097 patients.   Of these 82 patients, the most common neuropathy was a large fiber neuropathy (68.3%):  including neurophysiological assessment demonstrating 36 (44%) symmetric axonal neuropathies and 42 (51%) patients with a pure axonal loss, 18 patients had small-fiber neuropathies, characterized by decreased intra-epidermal nerve fiber density and/or morphological changes of unmyelinated fibers on skin biopsy.   Altogether, patients with neuropathies were older at time of SLE diagnosis (39.16 versus 32.05, p<0.0001), had an increased risk of Zoster infection, but otherwise had similar profile of SLE-related clinical and laboratory features).

Conclusion: Our characterization of small-fiber neuropathy in patients, has never been systematically evaluated and reported in unselected SLE cohorts, and suggests that this neuropathy may be an unrecognized cause of morbidity in SLE patients.   SLE patients with neuropathies versus without neuropathies shared similar clinical and immunological features.  Given the tropism of VZV for peripheral neuronal structures, prospective studies are warranted to evaluate whether re-activation of VZV is a risk factor for SLE neuropathies.


Disclosure:

A. Oomatia,
None;

H. Fang,
None;

M. Petri,
None;

J. Birnbaum,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/peripheral-neuropathy-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology